Evaluation of the World Health Organisation antibody-testing strategy for the individual patient diagnosis of HIV infection (strategy III).
To evaluate the World Health Organisation (WHO) antibody testing strategy for the individual patient diagnosis of HIV infection (strategy III). Evaluation of a combination of enzyme-linked immunosorbent assays (ELISAs) for the detection of antibodies to HIV-1 and HIV-2 infection. The WHO strategy III calls for a combination of three ELISAs, based on different antigens and/or differing test principles, to be used in a sequential fashion. The first part of the study evaluated various kits as part of a selection process. The second part of the study was an assessment of the three-ELISA testing strategy on routine sera submitted to the National Institute for Virology (NIV) for HIV testing. In all instances, the conventional testing protocol, which utilises a screening ELISA followed by a confirmatory Western blot (WB) on positive specimens, was used as the 'gold standard'. The HIV-testing laboratory at the NIV, Johannesburg. In the first part of the study, all of the ELISA kits evaluated showed high sensitivity and specificity, and a selection of the kits for part two of the study was made in accordance with the WHO recommendation. The kits selected, in order of use, were the Biotest anti-HIV 1/2 (test 1), Pasteur Genelavia Mixt HIV-1/2 (test 2) and Murex Wellcozyme HIV-1 competitive assay (test 3). This combination was evaluated using 7,812 sera submitted to the NIV for serology testing. The sensitivities of the tests were highly satisfactory (99.6-100%) as were the specificities (99.2-100%). The positive predictive value of strategy III at various seroprevalence (0.5-25.5%) was > or = 99.6%. The rate of WB usage when compared with the previous HIV testing protocol was low (4.6%). The results of this study suggest that this testing protocol could be introduced in South Africa with considerable cost-saving and no reduction in specificity.